Latest Financial Results
Q1 2025
Quarterly Results
Ended Jan 31, 2025
Stock Information
Symbol
ANIXPrice
Change
Volume
52 week Low/High
Day Low/High
Company Overview
Anixa is a clinical-stage biotechnology company focused on the treatment and prevention of cancer. Anixa's therapeutic portfolio consists of an ovarian cancer immunotherapy program being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR-T, known as chimeric endocrine receptor-T cell (CER-T) technology. The Company's vaccine portfolio includes vaccines being developed in collaboration with Cleveland Clinic to treat and prevent breast cancer and ovarian cancer, as well as additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, colon, and prostate. These vaccine technologies focus on immunizing against "retired" proteins that have been found to be expressed in certain forms of cancer. Anixa's unique business model of partnering with world-renowned research institutions on all stages of development allows the Company to continually examine emerging technologies in complementary fields for further development and commercialization.
Latest News & Events
Anixa Biosciences Enters Letter of Intent with VERDI Solutions to Develop Artificial Intelligence-Guided Personalized and Off-the-Shelf Cancer Vaccines
Read More...Anixa Biosciences Receives Notice of Allowance from USPTO for Ovarian Cancer Vaccine
Read More...Anixa Biosciences CEO to Present at the 2025 CAGLA NeauxCancer Conference on March 28th
Read More...